|
|
|
|
| LEADER |
02384nam a22004335i 4500 |
| 001 |
978-3-319-46091-8 |
| 003 |
DE-He213 |
| 005 |
20161107143620.0 |
| 007 |
cr nn 008mamaa |
| 008 |
161107s2016 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319460918
|9 978-3-319-46091-8
|
| 024 |
7 |
|
|a 10.1007/978-3-319-46091-8
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Resistance to Tyrosine Kinase Inhibitors
|h [electronic resource] /
|c edited by Daniele Focosi.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2016.
|
| 300 |
|
|
|a XIII, 188 p. 8 illus., 6 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501
|
| 505 |
0 |
|
|a Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.
|
| 520 |
|
|
|a The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 700 |
1 |
|
|a Focosi, Daniele.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319460901
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-46091-8
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
